ReviewNeurochemical research2025
Regulatory Landscapes of Protein Acylations in Neuroinflammation: From Molecular Mechanisms to Therapeutic Targets.
Review in Neurochemical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lysine β-hydroxybutyrylation as a drought-responsive epigenetic mark in rice.Cell discovery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
In recent years, the role of novel protein acylation modifications in neuroinflammation has gradually become a hot research topic. In this paper, we reviewed the molecular mechanisms of five types of acylation modifications, namely lactylation (Kla), succinylation (Ksucc), crotonylation (Kcr), β-hydroxybutyrylation (Kbhb) and palmitoylation, and their association with neuroinflammation. To clarify the roles of these acylation modifications in neuroinflammation, we summarized the acyl donors, key regulatory enzymes (acyltransferases and deacylases), and dynamic regulatory networks for each modification type. On the one hand, they are directly involved in the inflammatory response by regulating microglial activation and pro-inflammatory factor release; on the other hand, they can indirectly affect the neurodegenerative disease process through metabolic reprogramming. This article also discusses drug development for novel acylases, including strategies based on enzyme activity inhibition or metabolic intervention, and points out the limitations of current studies. Future studies need to explore the spatial and temporal dynamics of acylation modifications, cross-regulatory networks and their functions in the neuroimmune microenvironment to provide new targets for the development of precise anti-neuroinflammatory therapies. The discovery of novel acylation modifications not only expands the theoretical framework of protein post-translational modification (PTM), but also opens up a multi-dimensional intervention pathway for the treatment of neuroinflammation-related diseases.
Indexed as
Identifiers
41460381What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.